Properties
What is it?
Ergoferon Description Dosage Form: Lozenges Tablets Composition (per 1 tablet): Antibodies to human gamma-interferon, affinity purified – 0.006 g* Antibodies to histamine, affinity purified – 0.006 g* Antibodies to CD4, affinity purified – 0.006 g* Excipients: lactose – 0.267 g, microcrystalline cellulose – 0.03 g, magnesium stearate – 0.003 g. * expressed per lactose monohydrate in the form of a water-alcohol mixture of 3 active components, diluted 10012, 10030, 10050 times, respectively. Description: Flat cylindrical tablets with a bevel and a score line, white to almost white in color. The inscription MATERIA MEDICA is applied to one flat side, and ERGOFERON to the other flat side. Pharmacotherapeutic Group: Antiviral agent. Pharmacological Properties Pharmacodynamics: The spectrum of pharmacological activity of Ergoferon includes antiviral, immunomodulatory, and anti-inflammatory effects. The efficacy of Ergoferon components in viral infectious diseases has been experimentally and clinically established: influenza A and influenza B, acute respiratory viral infections (caused by parainfluenza viruses, adenoviruses, respiratory syncytial viruses), herpesviral infections (labial herpes, ophthalmic herpes, genital herpes, herpes zoster, chickenpox, infectious mononucleosis). Ergoferon has prophylactic efficacy against acute respiratory viral infections of non-influenza origin, and prevents the development of intercurrent diseases in the post-vaccination period. The components of the preparation have a unified mechanism of action, increasing the functional activity of CD4 receptors, gamma-interferon receptors (IFN-γ), and histamine receptors, which is accompanied by a pronounced immunotropic effect. It has been experimentally confirmed that antibodies to gamma-interferon: increase the expression of IFN-γ and IFN-α/β, as well as associated interleukins (IL-2, IL-4, IL-10, etc.), improve interferon-ligand-receptor interactions, restore cytokine status; normalize the concentration and functional activity of natural IFN-γ antibodies, which are an important factor in the body's natural antiviral tolerance; stimulate interferon-dependent biological processes: induction of expression of major histocompatibility complex antigens of types I and II and Fc receptors, monocyte activation, stimulation of NK cell functional activity, regulation of immunoglobulin synthesis, activation of mixed Th1 and Th2 immune responses. Antibodies to CD4, presumably acting as allosteric modulators of the indicated receptor, regulate the functional activity of the CD4 receptor, leading to increased functional activity of CD4 lymphocytes, normalization of the CD4/CD8 immunoregulatory index, and subpopulation composition of immunocompetent cells (CD3, CD4, CD8, CD16, CD20). Antibodies to histamine inhibit the histamine-dependent activation of peripheral and central H1 receptors, thereby reducing the tone of bronchial smooth muscles, reducing capillary permeability, which leads to a decrease in the duration and severity of rhinorrhea, swelling of the nasal mucosa, cough and sneezing, as well as the severity of allergic reactions accompanying the infectious process, by reducing the release of histamine from mast cells and basophils, the production of leukotrienes, the synthesis of adhesion molecules, the chemotaxis of eosinophils, and suppressing platelet aggregation upon contact with allergens. The combined use of the components of the complex preparation enhances the antiviral activity of its components. Pharmacokinetics: The sensitivity of modern physicochemical analysis methods (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow for the assessment of the content of even minimal doses of antibodies in biological fluids, organs, and tissues, which makes it technically impossible to study the pharmacokinetics of the drug Ergoferon. Indications for Use: Treatment and prevention of influenza A and B. Prevention and treatment of acute respiratory viral infections caused by parainfluenza virus, adenovirus, respiratory syncytial virus. Prevention and treatment of herpesviral infections (labial herpes, ophthalmic herpes, genital herpes, chickenpox, herpes zoster, infectious mononucleosis). Prevention and treatment of acute intestinal infections of viral etiology (caused by adenovirus). For the prevention of bacterial complications of viral infections, prevents the development of superinfection. Contraindications: Increased individual sensitivity to the components of the preparation. Pregnancy and Lactation: The safety of Ergoferon use during pregnancy and lactation has not been studied. When the drug is necessary, the risk/benefit ratio should be considered. Method of Administration and Dosage: Take orally. 1 tablet per dose (but not during meals). The tablet should not be swallowed; it should be kept in the mouth until completely dissolved. For children from 6 months of age. When prescribed for young children (6 months to 3 years), it is recommended to dissolve the tablet in a small amount (1 tablespoon) of boiled water at room temperature. Treatment should be started as soon as possible, immediately after the first signs of acute infection, according to the following scheme: for the first 2 hours, the preparation is taken every 30 minutes, then three more doses are taken during the first day at equal time intervals. From the second day onwards, take 1 tablet 3 times a day until complete recovery. For the prevention of viral infectious diseases. The duration of the prophylactic course is determined individually and can range from 1 to 6 months. If necessary, the preparation can be combined with other antiviral and symptomatic agents. Side Effects: Individual hypersensitivity reactions to the components of the preparation may develop. Overdose: In case of accidental overdose, dyspeptic phenomena caused by the excipients in the preparation may occur. Interaction with Other Medicinal Products: No cases of interaction with other medicinal products have been registered to date. Special Instructions: The preparation contains lactose monohydrate; therefore, its administration is not recommended for patients with congenital galactosemia, glucose-galactose malabsorption syndrome, or congenital lactase deficiency. Ergoferon does not affect the ability to drive vehicles and operate other potentially dangerous mechanisms. Dosage Form: Homeopathic lozenges. 20 tablets in a polyvinyl chloride and aluminum foil blister pack. 1, 2, or 5 blister packs, along with instructions for use, are placed in a cardboard box. Storage Conditions: Store in a protected place from light at a temperature not exceeding 25°C. Keep out of reach of children. Shelf Life: 3 years. Do not use after the expiry date. Conditions of Dispensing from Pharmacy: Pharmaceutical product group III, available without a prescription.